, 15:319

Viral Hepatitis: Review of Arthritic Complications and Therapy for Arthritis in the Presence of Active HBV/HCV

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Chronic infection with hepatitis B (HBV) or C (HCV) virus, which currently affect approximately 7 % of the world population, is encountered with the same frequency among patients with arthritis starting biological or non-biological disease-modifying anti-rheumatic drugs (DMARDs). Treatment with biological agents, including anti-tumor necrosis factor agents, rituximab, and abatacept, without appropriate antiviral therapy has been associated with reactivation of HBV infection which in some cases can lead to life-threatening complications, indicating the need for appropriate screening and treatment of these patients. In this review, the latest data regarding HBV or HCV-related arthritic complications and treatment of rheumatic diseases in the presence of chronic HBV or HCV infection will be critically presented.

This article is part of the Topical Collection on Infections and Arthritis